At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 100 enrolled
Drug / intervention
Desonide Cream 0.05% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Investigator-Blind, Six-Week, Parallel Group, Multicenter Pilot Study to Compare the Safety and Efficacy of EpiCeram Skin Barrier Emulsion and Desonide Cream 0.05% in the Twice Daily Treatment of Pediatric Subjects With Moderate Atopic Dermatitis
In Brief
A Phase 4 clinical trial evaluating EpiCeram Skin Barrier Emulsion and Desonide Cream 0.05% for Atopic Dermatitis. Completed, enrolled 100 participants across 5 sites.
Detailed Summary
This study compares the effectiveness of two topical creams for atopic dermatitis in pediatric subjects. Subjects will be randomly assigned to use one of the two creams twice daily for 6 weeks or until clear.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2009
Enrollment StartMar 2009
Primary CompletionAug 2009
TodayJul 2026
First PostedJan 26, 2009
Enrollment StartMar 1, 2009
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.4 years ago
Interventions
EpiCeram Skin Barrier Emulsiondevice
topical cream, twice daily, 6 weeks
Desonide Cream 0.05%drug
topical cream, twice daily, 6 weeks